ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ドルゾラミド

Dorzolamide

HCID 5284549
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
120279-96-1
標準SMILES
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
InChIKey
IAVUPMFITXYVAF-XPUUQOCRSA-N
分子式
C10H16N2O4S3
平均分子量
324.4 g/mol
単同位体質量
324.02722052

概要

Dorzolamide is 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor, an antihypertensive agent and an antiglaucoma drug. It is a member of thiophenes and a sulfonamide.

名称と識別子

優先名称
Dorzolamide
IUPAC
(4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
現地名
ドルゾラミド
英語名
Dorzolamide
分子式
C10H16N2O4S3
分子量
324.44

名称と別名

dorzolamide120279-96-14S,6S-DorzolamideDorzolamidaDorzolamide, trans-(-)-9JDX055TW1CHEBI:4702DTXSID7022960(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide(4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
名称をさらに表示
ドルゾラミドドルゾルアミド(4S,6S)-2-(アミノスルホニル)-4-(エチルアミノ)-6-メチル-5,6-ジヒドロ-4H-チエノ[2,3-b]チオピラン7,7-ジオキシド(4S,6S)-4-(エチルアミノ)-6-メチル-5,6-ジヒドロ-4H-チエノ[2,3-b]チオピラン-2-スルホンアミド7,7-ジオキシド(4S)-4β-エチルアミノ-5,6-ジヒドロ-6α-メチル-2-スルファモイル-4H-チエノ[2,3-b]チオピラン7,7-ジオキシド(4S)-4β-(エチルアミノ)-5,6-ジヒドロ-6α-メチル-4H-チエノ[2,3-b]チオピラン-2-スルホンアミド7,7-ジオキシド(4S)-2-スルファモイル-4β-(エチルアミノ)-6α-メチル-5,6-ジヒドロ-4H-チエノ[2,3-b]チオピラン7,7-ジオキシド2-(アミノスルホニル)-4β-(エチルアミノ)-6α-メチル-5,6-ジヒドロ-4H-チエノ[2,3-b]チオピラン7,7-ジオキシド

物性

構造計算による物性補完中

XLogP
0.4
極性表面積
151 Ų
水素結合供与体数
2
水素結合受容体数
7
回転可能結合数
3
重原子数
19
形式電荷
0
複雑度
534

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 2 件

-1

0.27

Solubility6.99e-01 g/L
Human Drugs · 2 件

Breast Feeding; Lactation; Antiglaucoma Agents; Carbonic Anhydrase Inhibitors

Pharmaceuticals

Melting Point283 - 285 °C
Physical DescriptionSolid

物理化学的性質

沸点
575.8 · 575.8±60.0 °C(Predicted)
比重(密度)
1.53 · 1.53±0.1 g/cm3(Predicted)
貯蔵温度
room temp
溶解性
5 mg/mL · DMSO: 可溶5mg/mL (透明溶液、加温)
酸解離定数(Pka)
6.35 · pKa 6.35 (Uncertain);8.50 (Uncertain)
外見
粉
色
白からベージュ
InChI
1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H315 (97.4%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

毒性情報

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
3
rtecs
XJ9095169
risk_code
36/37/38
hazard_code
Xi
safety_code
26
Hazard Classifications
Acute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 2 件

S - Sensory organs

QS - Sensory organs

Protein BindingDorzolamide is approximately 33% bound to plasma proteins.
Pharmacodynamics · 1 件

Dorzolamide is a carbonic anhydrase inhibitor that reduces elevated intraocular pressure in open-angle glaucoma or ocular hypertension. When used in combination with topic beta-adrenergic antagonists, dorzolamide has an additive effect of lowering intraocular pressure. The peak ocular hypotensive effect of dorzolamide is observed at about 2 hours following ophthalmic administration.

Mechanism of Action · 1 件

Elevated intraocular pressure is a characteristic manifestation of ocular hypertension or open-angle glaucoma. The level of intraocular pressure (IOP) is governed by the balance between the production of aqueous humour (by ocular ciliary processes) and its outflow from the anterior segment of the eye via trabecular (conventional) or uveoscleral (unconventional) pathways. When there is an increase in the resistance to the trabecular outflow of aqueous humour, the intraocular pressure is elevated. Subsequently, optic nerve damage can occur from blood flow restrictions and mechanical distortion of ocular structures. Optic nerve damage can further result in optic disc cupping and progressive visual field loss (and blindness in some cases). Carbonic anhydrase (CA) is a ubiquitous enzyme that catalyzes the reversible hydration of carbon dioxide to bicarbonate ions and dehydration of carbonic acid. In the ocular ciliary processes, the local production of bicarbonate by CAs promotes sodium and fluid transport. CA-II is a key isoenzyme found primarily in red blood cells (RBCs) that regulates aqueous humour production. Dorzolamide is a highly specific CA-II inhibitor, where it displays a 4000-fold higher affinity for carbonic anhydrase II than carbonic anhydrase I. The inhibition of CA-II in the ciliary process disrupts the formation of bicarbonate ions and reduces sodium and fluid transport, which leads to decreased aqueous humour secretion and reduced intraocular pressure.

Biological Half-Life · 1 件

As the drug administration is stopped, dorzolamide stored in RBCs is washed out of RBCs in a non-linear fashion, with the terminal elimination half-life of ≥120 days in RBCs. This initial rapid decline in drug concentrations is followed by the slow elimination phase, where the elimination half-life of the drug is about >4 months.

関連反応

2 件
反応記録を作成
HRID 348779 の反応式
HRID 348779反応物として
HRID 1928583 の反応式
HRID 1928583反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
(4S,6S)-4-(エチルアミノ)-6-メチル-2-スルファモイル-4H,5H,6H,7H-チエノ[2,3-b]チオピラン-7,7-ジイウム-7,7-ビス(オラート)
(4S)-4β-(エチルアミノ)-6α-メチル-2-スルファモイル-5,6-ジヒドロ-4H-チエノ[2,3-b]チオピラン7,7-ジオキシド
(4S)-4β-(エチルアミノ)-5,6-ジヒドロ-6α-メチル-2-スルファモイル-4H-チエノ[2,3-b]チオピラン7,7-ジオキシド
(2r,4r)-2-ethylamino-4-methyl-5,5-dioxo-5,7-dithiabicyclo[4.3.0]nona-8,10-diene-8-sulfonamide
C06969
Dorzolamide-d5 Maleate
Dorzolamide >=98% (HPLC)
Dorzalamide hydrochloride
DORZOLAMIDE(SUBJECTTOPATENTFREE)
Dorzolamide Impurity A Hydrochloride
(4S,6S)-4-(ethylamino)-5,6-dihydro-6-methyl-7,
4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S-trans)-DorzolamidumDorzant4-ethylamino-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno(5,4-b)thiopyran-2-sulfonamide4-ethylamino-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[5,4-b]thiopyran-2-sulfonamide(2S,4S)-4-(ethylamino)-2-methyl-1,1-dioxo-2H,3H,4H-1$l^(6),7-thieno(2,3-b)(1$l^(6))thiopyran-6-sulfonamide(2S,4S)-4-(ethylamino)-2-methyl-1,1-dioxo-2H,3H,4H-1$l^{6},7-thieno[2,3-b][1$l^{6}]thiopyran-6-sulfonamide(4S,6S)-4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno(2,3-b)thiopyran-2-sulfonic acid amide

データベース識別子

CAS
120279-96-1
PubChem CID
5284549
DTXSID
DTXSID7022960
ChEMBL
CHEMBL218490
ChEBI
CHEBI:4702
UNII
9JDX055TW1
EC Number
802-371-1
InChIKey
IAVUPMFITXYVAF-XPUUQOCRSA-N
SMILES
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O
CAS データベース
120279 · 120279-96-1(CAS DataBase Reference)
Metabolism/Metabolites · 1 件

Dorzolamide is slowly metabolised to N-desethyldorzolamide, which has a less potent pharmacological activity on CA-II and some inhibitory effect on CA-I. Like the parent drug, N-desethyldorzolamide is also stored in RBCs, where it binds to CA-I. The findings of an _in vitro_ study using liver microsomes from Sprague-Dawley rats suggest the involvement of CYP2B1, CYP2E1, and CYP3A2 in the metabolism of dorzolamide in rat liver.

FDA Pharmacological Classification · 6 件

9JDX055TW1

DORZOLAMIDE

Established Pharmacologic Class [EPC] - Carbonic Anhydrase Inhibitor

Mechanisms of Action [MoA] - Carbonic Anhydrase Inhibitors

Dorzolamide is a Carbonic Anhydrase Inhibitor. The mechanism of action of dorzolamide is as a Carbonic Anhydrase Inhibitor.

DORZOLAMIDE

MeSH Pharmacological Classification · 2 件

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES.

Absorption, Distribution and Excretion · 4 件

Dorzolamide readily penetrated into the eye in animal studies. Upon ophthalmic administration, dorzolamide is absorbed via the cornea and stroma. Dorzolamide is reported to be absorbed systematically following topical administration. The systemic exposure of dorzolamide following long-term administration was assessed in healthy subjects receiving an oral dose of 2 mg dorzolamide twice daily, which equates to the ophthalmic dose of 2% dorzolamide three times daily. In these subjects receiving the treatment for 20 weeks, the steady-state was reached within 8 weeks.

Dorzolamide is primarily excreted unchanged in the urine; however, N-desethyldorzolamide is also detected in the urine.

There is limited information on the volume of distribution of dorzolamide; however, the plasma concentrations of dorzolamide and its main metabolite are generally below the assay limit of quantitation, which is 15nM. Dorzolamide accumulates in red blood cells following chronic administration as a result of binding to CA-II, which is contained in peripheral red blood cells (RBCs).

There is limited information on the clearance rate of dorzolamide.

Cellular LocationsCytoplasm

用途と製造

UsesUse (kg; approx.) in Germany (2009): >250
Use ClassificationPharmaceuticals

応用分野

使用Dorzolamide is an intermediate in synthesizing N-Acetyl Dorzolamide (A173640), a useful synthetic compound.

上流・下流製品情報

下流製品

ドルゾラミド塩酸塩
補足説明 · 1 件

定義ChEBI: 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration . A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.